A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 208
- 试验地点
- 81
- 主要终点
- Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
研究概览
简要总结
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); high-grade B-cell lymphoma (NOS or double/triple hit); transformed follicular lymphoma; follicular lymphoma Grade 3b
- •Have disease relapsed or refractory to at least one prior systemic therapy for aggressive non-Hodgkin's lymphoma (aNHL)
- •Participants who have received only one prior line of therapy must be ineligible for autologous stem cell transplant (ASCT)
- •Measurable disease
- •Adequate hepatic, hematologic, and renal function
- •Estimated creatinine clearance (CrCl) ≥ 30 mL/min by Cockroft-Gault method or other institutional standard methods
- •Negative HIV test at screening. Participants with a positive HIV test at screening are eligible provided that, prior to enrollment, they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count of at least 200 microliters, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
排除标准
- •Pregnant or breast feeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab, 9 months after the final dose of polatuzumab vedotin, 12 months after the final dose of rituximab, 6 months after the final dose of gemcitabine, 9 months after the final dose of oxaliplatin, and 3 months after the final dose of tocilizumab, as applicable
- •Inability to comply with protocol-mandated activity restrictions
- •Prior treatment with mosunetuzumab or other CD-20-directed bispecific antibodies, or R-GemOx or Gem-Ox
- •Prior treatment with polatuzumab vedotin, with the following exceptions: participants who have a documented response (partial response or complete response) to polatuzumab vedotin and an absence of PD within 12 months from the last dose of polatuzumab vedotin; participants who received up to 2 doses of a polatuzumab vedotin-containing regimen as bridging to CAR-T therapy, and either has a documented disease control (stable disease, partial response, or complete response), or were not assessed for response following treatment with polatuzumab vedotin
- •Contraindication to any component of the study treatment
- •Grade > 1 peripheral neuropathy
- •Participants with Grade > 1 persistent toxicity related to prior anti-lymphoma treatment (except for alopecia and anorexia, or other toxicities not considered a safety risk for the participant per investigator's judgment)
- •Received anti-lymphoma treatments with monoclonal antibodies, radio-immunoconjugates or antibody-drug conjugates (ADCs) within 4 weeks before the first dose of study treatment
- •Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
- •Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
- •ASCT within 100 days prior to the first study treatment administration
- •Prior treatment with chimeric antigen receptor (CAR) T cell therapy within 30 days before the first study treatment administration
- •Prior allogenic stem cell transplant (SCT)
- •Have had a solid organ transplantation
- •Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- •History of confirmed progressive multifocal leukoencephalopathy
- •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombination antibody-related fusion proteins)
- •History of other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of malignancies with a negligible risk of metastasis or death
- •Currently have or have had a past history of central nervous system (CNS) involvement of lymphoma
- •Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator, or with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications, are allowed
- •Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
- •Significant active pulmonary disease
- •Participants with active symptoms of interstitial lung disease and/or pneumonitis, or those with a history of interstitial lung disease and/or pneumonitis within 6 months prior to the first dose of study treatment
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to the first study treatment administration
- •Known or suspected chronic active Epstein-Barr virus (EBV) infection
- •Recent major surgery within 4 weeks prior to the first study treatment administration
- •Positive test results for chronic hepatitis B infection
- •Acute or chronic hepatitis C virus (HCV) infection
- •Have been administered a live, attenuated vaccine within 4 weeks before the first dose of study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
- •Participants who have positive SARS-CoV-2 test within 7 days prior to enrollment (rapid antigen test result is acceptable)
- •History of autoimmune disease
- •Received investigational therapy, whether or not intended for lymphoma treatment, within 7 days prior to initiation of study treatment
- •Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
研究组 & 干预措施
M+P (Arm A)
Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
干预措施: Polatuzumab vedotin (Drug)
M+P (Arm A)
Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
干预措施: Tocilizumab (Drug)
M+P (Arm A)
Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
干预措施: Mosunetuzumab (Drug)
R-GemOx (Arm B)
Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
干预措施: Gemcitabine (Drug)
R-GemOx (Arm B)
Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
干预措施: Oxaliplatin (Drug)
R-GemOx (Arm B)
Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
干预措施: Rituximab (Drug)
结局指标
主要结局
Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
时间窗: Up to approximately 23.8 months
ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.
Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
时间窗: Up to 32 months
PFS was defined as the time from randomization to first occurrence of disease progression (PD) or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.
次要结局
- ORR as Determined by the IRF, According to LRC Using PET-CT or CT Scans in ITT Population(Up to 32 months)
- ORR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans in ITT Population(Up to approximately 58 months)
- Duration of Response (DoR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans(Up to 32 months)
- DoR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans(Up to approximately 58 months)
- Overall Survival (OS)(Up to 32 months)
- PFS as Determined by the Investigator, According to LRC Using PET-CT or CT Scans(Up to approximately 58 months)
- Complete Response Rate (CRR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans(Up to approximately 58 months)
- CRR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans(Up to approximately 58 months)
- Duration of Complete Response (DOCR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans(Up to 32 months)
- DOCR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans(Up to approximately 58 months)
- Time to Deterioration in Physical Functioning (PF), as Measured by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire-Core 30 (EORTC QLQ-C30)(Up to approximately 58 months)
- Time to Deterioration in Fatigue Scale, as Measured by the EORTC QLQ-C30(Up to approximately 58 months)
- Time to Deterioration in Lymphoma Symptoms, as Measured by Functional Assessment of Cancer Therapy- Lymphoma Questionnaire (FACT- Lym LymS)(Up to approximately 58 months)
- Number of Participants With Adverse Events (AEs)(Up to approximately 58 months)
- Number of Participants With Cytokine Release Syndrome (CRS) With Severity Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale(Up to approximately 58 months)
- Number of Participants With Dose Interruptions, Dose Reductions and Study Treatment Discontinuation Due to AEs(Up to approximately 58 months)
- Dose Intensity of Mosunetuzumab(Up to approximately 58 months)
- Change From Baseline in Peripheral Neuropathy (PN), as Measured by the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)(Up to approximately 58 months)